If you checked the stock market on Wednesday and saw Moderna stock suddenly exploding higher, you weren’t looking at a typo.

Shares of Moderna (NASDAQ: MRNA) closed at $174.38 on August 19, 2026, gaining roughly 177% in a single trading session. The extraordinary move came after Moderna and pharmaceutical giant Merck announced positive Phase 3 results for an experimental personalized mRNA cancer therapy targeting melanoma.

For a company best known for its COVID-19 vaccine, this could be one of the most important developments in Moderna’s history.

So, why is Moderna stock up so much today?

The answer comes down to one major breakthrough—and what investors believe it could mean for Moderna’s future.

Moderna’s Cancer Treatment Just Passed a Huge Phase 3 Test

The biggest reason MRNA stock is soaring is the success of a late-stage clinical trial called INTerpath-001.

Moderna and Merck are jointly developing intismeran autogene, also known as V940 or mRNA-4157. The experimental treatment uses messenger RNA technology to create an individualized therapy based on mutations found inside each patient’s tumor.

It is being tested alongside Merck’s blockbuster cancer immunotherapy Keytruda.

On August 19, the companies announced that the Phase 3 study met both its primary endpoint of recurrence-free survival and a key secondary endpoint measuring distant metastasis-free survival. In simpler terms, patients receiving the combination experienced significantly better outcomes when it came to preventing melanoma from returning or spreading elsewhere in the body compared with Keytruda alone.

That is a major scientific milestone.

According to Moderna and Merck, this represents the first positive Phase 3 result for an individualized neoantigen therapy and an mRNA-based cancer therapy.

That explains why Wall Street reacted so dramatically.

What Exactly Is Moderna’s Personalized Cancer Vaccine?

Calling intismeran a “cancer vaccine” makes it sound somewhat similar to a traditional vaccine, but the technology is far more personalized.

Doctors take a sample of an individual patient’s tumor and identify mutations unique to that cancer.

Moderna then creates a personalized mRNA therapy containing instructions associated with as many as 34 tumor-specific neoantigens. The goal is essentially to teach the patient’s immune system which cancer cells it should recognize and attack.

The treatment is then combined with Keytruda, which helps the immune system fight cancer by blocking the PD-1 pathway.

That combination could potentially create a powerful one-two punch: identify the patient’s specific cancer mutations and then help unleash the immune system against them.

The Trial Included More Than 1,100 Melanoma Patients

This wasn’t a tiny early-stage experiment.

The Phase 3 INTerpath-001 trial enrolled 1,137 patients with high-risk Stage IIB through Stage IV melanoma whose tumors had been completely removed through surgery.

Patients were randomly assigned to receive either intismeran plus Keytruda or Keytruda alone.

At the planned interim analysis, the combination produced statistically significant and clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival. Moderna also said there were no new safety signals compared with what had previously been observed.

That scale matters to investors because Phase 3 trials are typically among the final and most important hurdles before a company seeks regulatory approval.

Moderna and Merck now plan to present the full data at an international medical meeting and discuss regulatory filings with authorities.

Why This Could Be Much Bigger Than Melanoma

The market isn’t simply valuing one potential melanoma drug.

Investors are looking at what these results could say about Moderna’s entire mRNA technology platform.

For years, one of the biggest questions surrounding Moderna has been whether its extraordinary success developing COVID vaccines could translate into successful medicines outside infectious diseases.

A positive Phase 3 cancer result provides investors with one of the strongest pieces of evidence yet that mRNA technology could have meaningful applications in oncology.

Moderna and Merck are already evaluating intismeran across multiple cancer types and stages, including non-small cell lung cancer, bladder cancer and renal cell carcinoma. Their broader INTerpath development program includes nine Phase 2 and Phase 3 studies.

That creates a much larger possibility.

If personalized mRNA therapy eventually works across several cancers, investors may begin viewing Moderna less as a COVID-vaccine company and more as a diversified biotechnology platform.

And that could dramatically change how Wall Street values MRNA stock.

Analysts See Billion-Dollar Potential

The potential commercial opportunity is another reason Moderna shares exploded higher.

Reuters reported that Barclays analysts previously estimated intismeran could eventually generate approximately $3 billion annually from melanoma alone by 2035.

That doesn’t include possible use in lung cancer or other tumor types currently being studied.

Reuters also reported that Moderna President Stephen Hoge believes patients potentially could gain access to the treatment as early as 2027 if regulators approve it, although approval is not guaranteed.

For Moderna, a successful oncology franchise could provide something investors have been waiting years to see: a major new source of revenue beyond its respiratory vaccine business.

Moderna Was Already Building Momentum

Wednesday’s cancer announcement wasn’t Moderna’s only recent positive development.

On August 5, 2026, the FDA approved Moderna’s MFLUSIVA, an mRNA influenza vaccine for adults age 50 and older.

That gave Moderna another approved product and strengthened the company’s broader respiratory vaccine portfolio.

Moderna has also been working aggressively to reduce spending as COVID-related revenue has declined. In its latest quarterly results, the company reported approximately $145 million in second-quarter revenue, a GAAP net loss of roughly $800 million, and an improved forecast for year-end cash and investments of approximately $4.7 billion to $5.2 billion.

Those developments weren’t enough by themselves to cause a 177% rally.

But combined with the cancer breakthrough, they help explain why investors suddenly see a potentially different future for Moderna.

A Short Squeeze May Have Made the Rally Even Bigger

There’s another factor worth considering.

Moderna entered Wednesday with a substantial number of investors betting against the stock.

Reuters reported that short positions represented approximately 13.5% of Moderna’s freely traded shares before the rally. The enormous positive surprise created billions of dollars in paper losses for short sellers.

When a heavily shorted stock suddenly surges, traders betting against it may rush to buy shares to close their positions.

That buying can create a short squeeze, accelerating the rally even further.

So while the cancer trial was clearly the fundamental catalyst behind Moderna’s surge, short covering likely helped amplify the magnitude of the move.

Does This Mean Moderna’s Cancer Vaccine Is Approved?

No.

This is an important distinction.

Intismeran remains an investigational treatment.

The Phase 3 results are extremely encouraging, but Moderna and Merck have not yet released the complete clinical dataset. The trial is also continuing to evaluate additional endpoints, including overall survival, which examines whether patients receiving the treatment ultimately live longer.

Regulators will eventually have to review the complete evidence before deciding whether the treatment can be approved.

There are also commercial questions.

Because each treatment is individually manufactured based on a patient’s tumor, producing personalized cancer therapies at large scale could be more complicated than manufacturing conventional medicines.

Those uncertainties haven’t disappeared just because the stock jumped.

What Happens Next for MRNA Stock?

There are several major things investors will be watching next.

First will be the complete Phase 3 data. Moderna and Merck say those results will be presented at an upcoming international medical meeting.

Investors will want to know exactly how large the improvement was, how durable the benefit appears to be and what the complete safety profile looks like.

Second will be regulatory discussions. The companies have already indicated they intend to engage regulators about filing submissions.

Third will be results from intismeran trials in other types of cancer.

If the same individualized mRNA approach succeeds in additional tumors, the potential market opportunity could expand dramatically.

On the other hand, Moderna’s enormous one-day increase means a substantial amount of optimism is now reflected in its valuation. Future clinical disappointments, regulatory delays or commercialization challenges could therefore produce significant volatility.

The Bottom Line: Why Is Moderna Stock Up Today?

The answer is simple:

Moderna stock is soaring because the company may have just delivered one of the biggest validations yet of personalized mRNA cancer treatment.

Its experimental therapy intismeran, developed with Merck and combined with Keytruda, successfully met major endpoints in a large Phase 3 melanoma trial. It represents the first positive late-stage result of its kind for an individualized mRNA cancer therapy.

That sent Moderna shares from $62.96 on August 18 to $174.38 on August 19—a gain of approximately 177% in one day.

But the bigger story isn’t simply the stock move.

The results raise the possibility that Moderna’s mRNA platform could become a major force in cancer treatment—not just vaccines for infectious diseases.

For investors who have spent years asking what Moderna’s next chapter would look like after COVID, they may have just received their clearest answer yet.

Disclaimer: This article is for informational purposes only and should not be considered financial or investment advice.